12.10.2022
Publication in the journal Chest of the first study worldwide of an eNose that can diagnose the presence of a disease, in this case non-small cell lung cancer
Diagnosing non-small cell lung cancer by exhaled-breath profiling using an electronic nose: a multicentre validation study.
DOI : https://doi.org/10.1016/j.chest.2022.09.042
Sharina Kort, MD Dr.Marjolein Brusse-Keizer, Dr. Hugo Schouwink ……. Dr.Michel van den Heuvel, Dr. Wouter H. van Geffen, Dr Job van der Palen.
26.01.2022
Medtronic announces FDA approval of spinal cord stimulation therapy for treating chronic pain resulting from DPN
Medtronic has received US Food and Drug Administration (FDA) approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN).
Medtronic estimates that up to 800,000 US patients suffer from moderate to severe DPN symptoms that are not resolved through conventional medical management approaches, like drugs. The company views these patients as potential candidates for spinal cord stimulation (SCS).Charlie Covert, vice president and general manager of pain therapies at Medtronic, said: “DPN is a significant challenge for patients with diabetes, leading to disability and a diminished quality of life. This new indication enables us to apply Medtronic’s more than 40 years of proven SCS experience, as well as the company’s deep diabetes expertise, to deliver better care to even greater numbers of diabetes patients.” Independent studies show patients with DPN achieve significant pain relief when treated with SCS compared to conventional treatments alone1,2. A recent meta-analysis showed a significant improvement in health-related quality of life in patients treated with SCS compared to those receiving only conventional treatments3.
References:
1. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014 Nov;155(11):2426-31.
2. Slangen R, Schaper N, Faber C, et al. Spinal Cord Stimulation and Pain Relief in Painful Diabetic Peripheral Neuropathy: A Prospective Two-Center Randomized Controlled Trial. Diabetes Care. 2014;37:3016-3024.
3. Duarte RV, Nevitt S, Maden M, et al. Spinal cord stimulation for the management of painful diabetic neuropathy: a systematic review and meta-analysis of individual patient and aggregate data. Pain. March 2021.
De FDA approval voor de medtronic stimulatoren voor gebruik bij pijnlijke diabetische neuropathie is mede toegekend door de RCT (Randomized Controlled Trial)
Pain. 2014 Nov;155(11):2426-31. doi: 10.1016/j.pain.2014.08.031. Epub 2014 Aug 29.
Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial
Cecile C de Vos 1, Kaare Meier 2, Paul Brocades Zaalberg 3, Harold J A Nijhuis 4, Wim Duyvendak 5, Jan Vesper 6, Thomas P Enggaard 7, Mathieu W P M Lenders 8
12.11.2019
Zorginstituut Nederland > publications > position on neuromodulation in chronic pain.
Conditions for which neuromodulation is reimbursed in the Netherlands.
Neuromodulation via Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion Stimulation (DRGS) is reimbursed for the following conditions:
- failed neck surgery syndrome (FNSS) with persistent radicular (radiating) arm pain after neck surgery (SCS);
- complex regional pain syndrome (CRPS, tissue disruption after accident or surgery) with foot or leg pain (SCS and DRGS);
- complex regional pain syndrome other than under 3 (SCS);
- painful diabetic neuropathy (PDN, nerve pain due to diabetes) and small fiber neuropathy (disease affecting small nerve fibers, SCS).
The reimbursement of neuromodulation in painful diabetic neuropathy was partly awarded by the RCT (Randomized Controlled Trial).
Pain. 2014 Nov;155(11):2426-31. doi: 10.1016/j.pain.2014.08.031. Epub 2014 Aug 29.
Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial
Cecile C de Vos 1, Kaare Meier 2, Paul Brocades Zaalberg 3, Harold J A Nijhuis 4, Wim Duyvendak 5, Jan Vesper 6, Thomas P Enggaard 7, Mathieu W P M Lenders 8
21.03.2014
St. Jude Medical Announces the European Introduction of the Prodigy Neurostimulator for Spinal Cord Stimulation with Burst Technology
ST. PAUL, Minnesota (USA)–(BUSINESS WIRE)–St. Jude Medical, Inc. (NYSE:STJ), a global medical device manufacturer, announced yesterday the approval of the CE Mark and the European introduction of its Prodigy™ Burst Technology Neurostimulator for the treatment of chronic pain. As the first and only implantable neurostimulator with burst stimulation, the Prodigy neurostimulator is designed to reduce pain, improve patient satisfaction and enable reduced paresthesia (a tingling sensation associated with stimulation). The new device offers patients traditional spinal cord tonic stimulation (SCS, Spinal Cord Stimulation), in addition to burst technology that offers enhanced stimulation capabilities.
The CE marking for this form of stimulation was made possible in part by the study:
Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy.
Neuromodulation 2014 Feb 24;17(2):152-9. Epub 2013 Sep 24. Cecile C de Vos, Marjanne J Bom, Sven Vanneste, Mathieu W P M Lenders, Dirk de Ridder